jellypolice7Modafinil, a wakefulness-promoting agent, has garnered important attention since its introduction in the late 1990s. Initially permitted by the FDA for the treatment of narcolepsy, it has since been used off-label for varied cognitive enhancement purposes. This case study explores the pharmacological properties, clinical purposes, and ethical concerns surrounding modafinil, drawing on both scientific literature and anecdotal proof. |
0 entry(s) Showing 1 to 20
| Case Number | Domain(s) | Complainant | Respondent | Ruleset | Status |
